Virtus ETF Advisers’s Aldeyra Therapeutics ALDX Stock Holding History

Virtus ETF Advisers’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9,460	Closed	-$63.2K	–	429
2023 Q3	$63.2K	Sell	9,460 -941	-9%	-$6.98K	0.04%	399
2023 Q2	$87.3K	Buy	+10,401	New	+$102K	0.05%	422
2022 Q2	–	Sell	-22,945	Closed	-$102K	–	438
2022 Q1	$102K	Sell	22,945 -1,353	-6%	-$5.39K	0.05%	301
2021 Q4	$97K	Buy	24,298 +7,002	+40%	+$53.4K	0.04%	373
2021 Q3	$152K	Sell	17,296 -905	-5%	-$8.31K	0.07%	336
2021 Q2	$206K	Buy	+18,201	New	+$219K	0.08%	325

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtus ETF Advisers's ALDX Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 9,460 shares — an estimated $63.2K sold.

Virtus ETF Advisers first reported a position in ALDX in Q2 2021 and held it in 6 quarters. The position peaked at $206K in Q2 2021. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

Virtus ETF Advisers reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
Virtus ETF Advisers sold 9,460 Aldeyra Therapeutics shares in Q4 2023, an estimated $63.2K.
Virtus ETF Advisers first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 6 quarters.
Virtus ETF Advisers's Aldeyra Therapeutics position peaked at $206K in Q2 2021.
105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.